Organic Payment Gateways, a leading provider of specialized payment solutions, proudly announces the launch of its easily integrated payment gateway and merchant account program. This program is ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

As a result, it will be available only on private prescription at a cost of €215 or more a month. That equates to an annual ...

Novo Nordisk’s Saxenda has been recommended by NICE as a treatment for obesity, ending a 10-year drought in new drug therapies for weight management. The cost-effectiveness agency for England ...

The governing board of the State Health Plan is expected to give state treasurer Brad Briner the go-ahead Friday to overhaul ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Ivim Health raises concern over US FDA’s arbitrary critical deadline comes; submits Amicus brief to fighting patient access to GLP-1 medications: Columbus, Ohio Thursday, Februa ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

Prices, and the value of medicines ... allowing patients to record ingestion and share data with healthcare professionals. 7. Saxenda – are drugs really the answer to obesity?